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1. Introduction 
Congenital heart disease (CHD) is the most common human congenital defect, and a leading 
cause of death in infants. With an incidence that varies between 0.8 to 2% in neonates, 
congenital heart disease contributes to a much larger fraction of stillbirths.(Goldmuntz 2001; 
Loffredo 2000) Additionally, undiagnosed mild malformations of the heart often appear 
later in adulthood or remain undiagnosed for life. If these are included, some expect a 
prevalence of CHD that is up to 4% among all newborns.(Loffredo 2000) An additional 
contributor to the rising prevalence of CHD among adults is the advance in diagnostics and 
medical and surgical treatments of children with CHD, which is allowing them, in the 
majority of cases, to get their heart defect, fixed and sustain a normal life into 
adulthood.(van der Bom and others 2011) Management of the increasing number of adult 
patients living with CHD is becoming more and more complicated due to the fact that many 
patients with mild cardiac lesions are missed during childhood and later appear with 
complications due to these defects such as heart failure, but even more due to the 
improvements in diagnosis and surgical care of pediatric patients which are allowing them 
to survive to adulthood and have their own children.  
The majority of CHD is thought to result from gene mutations. This was suggested by early 
observations of Mendelian inheritance of CHD in families. Another evidence came from 
congenital syndromes due to micro and macro deletions of chromosomal regions that would 
result in CHD together with several other manifestations. Over the past few decades, and 
with the advent of gene sequencing and other techniques it became possible to identify the 
genetic causes of CHD.(Goldmuntz 2001) In syndromic cases, although it was possible to 
identify the chromosomal deletions causing the disease, in many cases the gene responsible 
for the heart phenotype remains undefined. Other syndromes were found to be due to 
single gene defects; however, for the majority, the downstream pathophysiology linking the 
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gene defect to the development of disease remains obscure. In parallel, extensive in-vitro and 
in-vivo studies widened our understanding of the molecular basis of heart development. It is 
thought that perturbations during embryonic heart development are at the origin of CHD. 
These studies resulted in large sets of candidate genes and molecular pathways involved in 
heart development. It is hypothesized that mutations in these genes cause CHD. This was 
confirmed by sequencing of genes encoding cardiac-enriched transcription factors such as 
GATA4, NKX2-5, and TBX5 in non-syndromic cases of CHD, and finding mutations that 
segregate with the disease. This prompted excitement in the field; however, screening of 
large cohorts of isolated CHD cases brought some disappointment as these genes explained 
only a minority of the cases. 
The understanding of how defects in these genes cause CHD turned out to be more 
complicated that initially expected. It became evident that not all CHD manifests true 
Mendelian inheritance. It is possible that combinations of mutations in different genes result 
in a particular phenotype, or combination of a gene mutation with a particular 
environmental exposure results in a CHD phenotype. Mutations might have low penetrance 
and only serve to increase the risk of CHD. Other mutations might yield totally defective 
proteins, yet be compensated for by other proteins in interlinked pathways. Copy Number 
Variations (CNVs), altered transcription, somatic mutations, and microRNA (miRNA) are 
also additional mechanisms through which the molecular basis of CHD can be explained. 
Current research explores all of these mechanisms with a wide array of technologies that are 
better than ever, and hence the future decade promises a near complete understanding of 
heart development and the genetic basis of Congenital Heart Disease.  
This chapter covers the genetics of syndromic and non-syndromic congenital heart disease. 
It discusses all genes that have been associated with congenital heart disease in humans 
with depiction of the spectrum of mutations and the genotype-phenotype correlations for 
each. The chapter also covers the roles of CNVs, epigenetics, somatic mutations, and miRNA 
in CHD. Current technologies and strategies used to understand the genetics of congenital 
heart disease are also discussed. The chapter ends with an explanation of how these 
technologies can unravel the genetics of CHD and allow the application of research findings 
for the benefit of patients.  
2. Classifications, anatomy, and clinical significance 
Congenital heart disease encompasses a broad category of anatomic malformations, which 
can range from a small septal defect or leaky valve to a severe malformation requiring 
extensive surgical repair or leading to death such as a single ventricle. Several classification 
systems exist for describing congenital heart disease. The most common classification used 
to describe CHD is purely clinical whereby CHD is cyanotic if the malformation results in 
deoxygenated blood bypassing the lung and causes cyanosis (blue patient), or non-cyanotic 
if the malformation does not result in cyanosis. The most common cyanotic heart defects are 
Tetralogy of Fallot (TOF), Hypoplastic Left Heart Syndrome (HLHS), Transposition of the 
Great Arteries (TGA), Truncus Arteriosus (TA), and Total Anomalous Pulmonary Venous 
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Connection (TAPVC).  Congenital heart defects can also be simple or complex. A complex 
malformation includes several simple malformations occurring together. The most typical 
example is Tetralogy of Fallot, which -as its name implies- includes four malformations: 
Pulmonary Stenosis (PS), an overriding aorta, Ventricular Septal Defect (VSD), and right 
ventricular hypertrophy.  Because of the wide diversity in the anatomy of the cardiac 
malformations, several detailed morphological classifications were also developed. The 
most widely recognized one is the International Pediatric and Congenital Cardiac Code 
(IPCCC), which was developed by the International Society for Nomenclature of Paediatric 
and Congenital Heart Disease (ISNPCHD). Table 1 shows the categories of CHD 
classifications of the IPCCC with the most common diagnoses within each category. The 
detailed version could be downloaded from the IPCCC website (www.ipccc.net). Other 
classification systems are radiologic based on echocardiography or magnetic resonance 
imaging, hemodynamic based on shunts and circulations in the heart, or embryological 
based on the presumed origin during heart development. CHD can occur as part of a 
syndrome and as such is labeled as syndromic or nonsyndromic, both of which are 
discussed in this chapter. In syndromic and non-syndromic cases, CHD can be isolated, that 
is occurring in a single patient, or familial afflicting many members within the same family. 
The recurrence rate of CHD after an isolated case is 2.7%. (Gill and others 2003)   
This anatomical heterogeneity of CHD has been one major reason why we know little about 
its genetics. Beyond the anatomical classification described in the IPCCC, different 
combinations of malformations and variations to described malformations can occur. 
Pediatric cardiologists often end up using different terminologies to describe similar defects 
because of their complexity. Extremely rare complex malformations are also sometimes 
described and run in families while their cause remains unknown.(Herrera and others 2008; 
Jaeggi and others 2008) Genotype-phenotype correlations are hard to establish due to this 
heterogeneity. In the majority of familial cases of CHD, there are different types of structural 
malformations within the same family. The same single gene mutation has been shown to 
cause a variety of cardiac defects, even within the same family.(Goldmuntz 2001)  Whenever 
mouse knockout models were developed to recapitulate a human CHD phenotype, the 
mouse phenotype was not always similar to that seen in humans.(Bruneau 2008) All these 
issues raised the hypothesis of a multifactorial and perhaps polygenetic origin of CHD. The 
genetic background of the individual, in-utero environment, epigenetic changes, and 
embryological hemodynamics and physiology are all possible causes of this phenotypic 
heterogeneity. 
Being a leading cause of deaths in the first year of life, CHD has prompted a large wave of 
development in surgical and interventional procedures to treat CHD. As such, CHD is 
mostly corrected with surgical and interventional procedures when the malformation causes 
symptoms or can cause heart failure such as a large septal defect or a cyanotic heart disease. 
Small malformations such as tiny septal defects that are expected to correct on their own or 
to not cause any complication are simply observed. With the recent advances in treatment, 
the mortality from CHD has decreased tremendously and most CHD patients survive a 
normal life throughout adulthood.(van der Bom and others 2011) This prompted a whole 
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new subspecialty in adult cardiology to take care of adult patients with CHD.(Moodie 1994) 
As these adults with CHD are planning to have children of their own, the recurrence risk 
became a problem, and this was yet another force to identify the genetic causes behind the 
disease, given that genetic counseling and pre-implantation genetic diagnosis (PGD) can be 
useful tools for these parents. 
 
Classification Category Most Common Diagnoses
Abnormalities of position 
and connection of the 
heart 
Dextrocardia
Atrial Situs Inversus 
Double Inlet Left Ventricle (DILV); Double Inlet Right Ventricle (DIRV) 
Transposition of the Great Arteries (TGA) 
Double Outlet Left Ventricle (DORV); Double Outlet Right Ventricle 
(DORV) 
Common Arterial Trunk (CAT), aka Truncus Arteriosus (TA) 
Tetralogy of Fallot and 
variants 
Tetralogy of Fallot (TOF)
Pulmonary Atresia (PA) and Venticular Septal Defect (VSD) 
Abnormalities of great 
veins 
Supervior Vena Cava (SVC) Abnormality
Inferior Vena Cava (SVC) Abnormality 
Coronary Sinus Abnormality 
Total Anomalous Pulmonary Venous Connection (TAPVC) 
Partially Anomalous Pulmonary Venous Connection (PAPVC) 
Abnormalities of atriums 
and atrial septum
Atrial Septal Defect (ASD)
Patent Foramen Ovale (PFO)
Abnormalities of AV 
valves and AV septal 
defect 
Tricuspid Regurgitation (TR)
Tricuspid Stenosis (TS) 
Ebstein’s Anomaly 
Mitral Regurgitation (MR) 
Mitral Stenosis (MS) 
Mitral Valve Proplapse (MVP) 
Atrioventricular Septal Defect (AVSD)
Abnormalities of 
ventricles and ventricular 
septum 
Single Ventricle
Ventricular imbalance: dominant LV +hypoplastic RV, or dominant 
RV+hypoplastic RV 
Aneurysm (RV, LV, or septal) 
Hypoplastic Left Heart Syndrome (HLHS) 
Double Chambered Right Ventricle (DCRV) 
Ventricular Septal Defect (VSD)
Abnormalities of VA 
valves and great arteries 
Aortopulmonary Window (AP Window)
Pulmonary Stenosis (PS), valvar or subalvar 
Pulmonary Artery Stenosis (PAS) 
Aortic Stenosis (AS), valvar or suvalvar 
Aortic Insufficiency (AI) 
Bicuspid Aortic Valve (BAV) 
Supravalvar Aortic Stenosis (SVS) 
Coarctation of the Aorta (COA) 
Interrupted Aortic Arach (IAA)
Abnormalities of 
coronary arteries, arterial 
duct and pericardium; 
AV fistulae
Anomalous Origin of Coronary Artery from Pulmonary Artery 
(ALCAPA) 
Patent Ductus Arteriosus (PDA) 
Table 1. IPCCC Classification of Congenital Heart Disease and Most Common Diagnoses 
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3. Developmental genetics of congenital heart disease 
Heart development is crucial to understand because its molecular basis is evolutionary 
conserved as depicted by studies in several model organisms. Heart development is a 
complex process regulated by combinatorial interactions of transcription factors and their 
regulators, ligands and receptors, signaling pathways, and contractile protein genes among 
others. The differential expression of each of these genes at unique stages of development 
and in different areas of the heart is responsible for the normal development of the heart. 
Any disruption in these genes will result in congenital malformations of the heart.  This 
molecular program for heart development has been a heavy field of research, yet our 
knowledge is far from being complete.  
The heart is the first organ to develop in the embryo at the second week of gestation when 
pre-cardiac lateral plate mesoderm cells migrate towards the midline of the embryo and 
form two crescent-shaped primordia, which fuse to form a beating heart tube at week 3. 
Within only few days the heart tube folds on itself in a process known as looping. This is 
the first event in the organogenesis of the embryo that manifests left-right asymmetry and 
is believed to be at the origin of the laterality program of the embryo. Subsequently, the 
four chambers of the heart are formed. This requires the differentiation of myocytes into 
two different subtypes, atrial and ventricular. Finally, valves and septa form through 
divisions within the heart to form the mature four-chambered heart. Valvulogenesis and 
septogenesis both require interaction between endocardial and myocardial cells, and 
valvoseptal malformations are the most common CHDs. In addition, development of the 
conduction system occurs into pacemakers and purkinjie cells, as well as vascularization 
from neural crest cells, and coronary arteries from epicardial precursor cells. As such, heart 
development requires a complex interplay of cell-commitment, migration, proliferation, 
differentiation, and apoptosis. Any perturbation in this program can result in congenital 
heart disease.  
Transcription factors regulate this tight program of gene expression, which is chamber-, 
and stage-specific. Protein interactions and formation of complexes that regulate 
downstream targets cardiac targets with convergent and divergent pathways have 
made the understanding of the molecular basis of CHD complicated. In-vitro and in-
vivo studies have been crucial in widening our understanding of the molecular 
program for heart development. Major transcription factor families involved in heart 
development include the GATA, T-box, homeobox, and basic Helix-Loop-Helix (bHLH) 
among others. Screening of human CHD patients for gene mutations within these 
transcription factor families as well as other cardiac-enriched genes implicated in heart 
development has not been as rewarding. Mutations in TBX5, GATA4, NKX2-5 have been 
implicated in many CHD families and genetic tests became clinically available. Several 
other genes have been clearly established to cause syndromic cases of CHD such as 
JAG1 and ELN. Deletions of chromosomal regions have also been established to cause 
several CHD syndromes, the most famous of which is DiGeorge Syndrome, which is 
caused by the 22q11.2 deletion. Despite all this progress, the majority of gene mutations 
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discovered in a family with CHD have not been confirmed in other families, or in only a 
few. Also screening of large cohorts of isolated CHD cases for mutations in a large set  
of cardiac-enriched candidate genes consistently results in a low yield of genetic 
causality.  
This gap has prompted novel directions in understanding the genetics of CHD. One of the 
hypotheses is the multifactorial and polygenetic nature of CHD, with gene mutations acting 
on a certain genetic background or acting within a particular susceptible environment 
within a developmental window. There have been efforts towards a new systems biology 
approach to understanding CHD. In addition to germline DNA sequencing which 
comprises the majority of the literature, somatic DNA sequencing, RNA sequencing, study 
of microRNAs (miRNAs), and Copy Number Variations (CNVs) analysis are becoming 
more popular tools to study CHD. Also with the advent of next-generation sequencing and 
the decreased cost of both sequencing and array comparative genomic hybridization (array-
CGH), more data are becoming available, and the molecular biology approach of the past 
few decades is shifting into a bioinformatics approach to help decipher the genetics of this 
complex disease. The subsequent sections of the chapter will dwell into the genetics of CHD 
from the oldest and most known to the most recent and least known. The below section 
discusses syndromic CHD, which comprises entities where the genetic causes is the most 
well established. Then the genes implicated in non-syndromic CHD in humans will be 
discussed with the degree of evidence for each. The most recent but least developed 
technologies to understand CHD mentioned above will be discussed at the end of the 
chapter.  
4. Syndromic congenital heart disease 
Cardiac malformations are among the most prevalent malformations in congenital 
syndromes. A large list of syndromes with congenital heart disease as a common 
manifestation has known genetic defects. CHD syndromes can be either due chromosome 
dosage disorders, large chromosomal deletions, small micro-deletions, or single gene 
defects. Table 2 shows a list of CHD syndromes within each of these categories with the 
corresponding genetic defect. This section will discuss the most common syndromes that 
include congenital heart disease as a primary manifestation. Within each syndrome, the 
phenotypic diversity as well as the spectrum of mutations and chromosomal defects that 
have been reported will be discussed.  
4.1. Down Syndrome (trisomy 21) 
Down Syndrome is the most common disorder of chromosome dosage with an incidence of 
1 in 700 to 1 in 800 live births. The incidence is known to increase tremendously with 
increased maternal age, particularly above the age of 35. The main clinical manifestations of 
Down Syndrome are characteristic dysmorphic facies, mental retardation, premature 
ageing, congenital heart disease, hearing loss, and increased risk of hematologic 
malignancies.(Pueschel 1990)  
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Syndrome with CHD Genetic Cause for CHD 
Disorders of Chromosome Dosage 
Trisomy 21 (Down Syndrome) Unknown 
Turner Unknown 
Chromosomal Microdeletions 
Di Georges Syndrome 
22q11.2 deletion resulting in absent 
TBX1 gene 
Williams-Beuren Syndrome 
Microdeletion of ELN gene; Mutations in 
ELN gene 
Single Gene Defects 
Holt-Oram Syndrome TBX5 mutations 
Alagille Syndome 
JAG1 or Notch1 mutations; 
Microdeletion or rearrangement at 
20p12 resulting in absent JAG1 gene 
Noonan Syndrome 
Mutations in PTPN11, SOS1, RAF1, 
KRAS, BRAF, MEK1, MEK2, and HRAS 
CHARGE Association 
Mutations in CHD7 and SEMA3E; 
Microdeletion at 22q11.2 
Char Syndrome Mutations in TFAP2B 
Ellis-can Creveld Syndrome Mutations in EVC or EVC2 
Cardiofaciocutaneous Syndrome 
Mutations in KRAS, BRAK, MEK1, or 
MEK2; Microdeletion at 12q21.2-q22 
Costello Syndrome 
Mutations in HRAS (overlap with 
Noonan and Cardiofaciocutaneous 
Syndrome) 
Marfan Syndrome Mutations in Fibrillin-1 
Table 2. Syndromes Manifesting Congenital Heart Disease and their Genetic Cause 
Congenital Heart Disease occurs in 40 to 50% of Down Syndrome patients. The most 
common abnormality is Atrioventricular Septal Defect (AVSD).(Marino 1993) Other 
malformations include VSD and TOF among others. Some CHD phenotypes are not seen in 
Down Syndrome patients such as Transposition of the Great Arteries (TGA) and Situs 
Inversus.(Marino 1993) Adult patients with Down Syndrome are also predisposed to Mitral 
Valve Prolapse (MVP) and fenestrations in the cusps of the aortic and pulmonary valves. 
(Hamada and others 1998)  
Given the complexity of the phenotype in Down Syndrome, there has been tremendous 
effort to build a phenotype map and identify the genetic cause behind each 
phenotype.(Delabar and others 1993; Korenberg and others 1994) Although successful for 
other features of Down Syndrome, the cause of the cardiac malformations in Down 
Syndrome are still unclear. Knowing that CRELD1 gene mutations have been associated 
with AVSD, one screening of 39 Down Syndrome patients identified two missense CRELD1 
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mutations and suggested that CRELD1 mutations might cause AVSD in Down 
Syndrome.(Maslen and others 2006) However other complex hypotheses have been 
suggested such as epigenetic mechanisms. Despite considerable process for molecular 
genetic analysis of Down Syndrome has been achieved using mouse models, to date no clear 
cause for CHD is known. 
4.2. Turner Syndrome  
Turner syndrome is a condition in females where all or part of one sex chromosome is absent. 
It is estimated to occur in 1 of 2500 females.(Bondy 2009) It manifests most commonly with 
characteristic physical features such as short stature, webbed necks, broad chest, low hairline, 
and low set ears, gonadal dysfunction, and cognitive deficits.(Bondy 2009) Clinical features 
are highly variable and can sometimes be very mild. Congenital heart disease is found in 20% 
to 50% of Turner Syndrome patients. The most common malformation is a Coarctation of the 
Aorta (COA) of the postductal type, which comprises 50% to 70% of CHD in Turner 
Syndrome.(Doswell and others 2006) Other cardiac malformations seen in Turner Syndrome 
include Bicuspid Aortic Valve (BAV), Partial Anomalous Pulmonary Venous Connection 
(PAPVC), and Hypoplastic Left Heart (HLH). In addition, a higher frequency of cardiac 
conduction abnormalities, hypertension, and aortic dilation has been reported in Turner 
Syndrome patients.(Doswell and others 2006; Lopez and others 2008) The molecular 
mechanisms leading to the cardiac malformations in Turner Syndrome are not clear.  
4.3. Di George Syndrome 
Di George Syndrome (DGS) is also known as Velocardiofacial Syndrome (VCFS) or 
Chromosome 22q11.2 Deletion Syndrome. It is caused by a 1.5 to 3.0-Mb hemizygous 
deletion on chromosome 22 q11, which can be inherited in an autosomal dominant fashion, 
but most commonly arises de novo.(Emanuel 2008) The clinical manifestations are highly 
variable owing to incomplete penetrance. When the disease is fully penetrant, clinical 
manifestations include cardiac outflow tract defects, parathyroid gland hypoplasia resulting 
in hypocalcaemia, thymus gland aplasia resulting in immunodeficiency, and neurologic and 
facial abnormalities.(Emanuel 2008) Cardiac outflow tact defects in DGS include TOF, type B 
Interrupted Aortic Arch (IAA), Truncus Arteriosus, Right Aortic Arch, and aberrant right 
subclavian artery.(Momma 2010) (Yagi and others 2003)  The molecular mechanisms leading 
to the phenotype in DGS are more known than for Down and Turner Syndromes. The 
microdeletion results in haploinsufficiency of the TBX1 gene, which is responsible for neural 
crest migration into the derivatives of the pharyngeal arches and pouches in the developing 
embryo.(Emanuel 2008) Target genes downstream of TBX1 are not yet elucidated, however 
they are most likely to explain the different phenotypes in DGS.  
4.4. Williams-Beuren Syndrome 
Williams-Beuren Syndrome (WBS) results from a hemizygous deletion of 1.5 to 1.8 Mb on 
chromosome 7q11.23, an area that encompasses 28 genes. Its prevalence is estimated to be 1 
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in 7500.(Stromme and others 2002) Clinically, patients have Supravalvular Aortic Stenosis 
(SVAS), mental retardation, characteristic facial features, distinctive dental anomalies, 
infantile hypercalcemia, and peripheral pulmonary artery stenosis.(Beuren and others 1962; 
Grimm and Wesselhoeft 1980; Williams and others 1961) The cardiac phenotype of vascular 
stenosis is caused by haploinsufficiency of the Elastin (ELN) gene and is found in at least 
70% of the patients.(Pober 2010) Mutations of the ELN gene also result in familial cases of 
SVAS without the syndromic features of Williams-Beuren.(Curran and others 1993; Metcalfe 
and others 2000) Although SVAS is the most common lesion in WBS patients, vascular 
stenoses can occur in any medium or large artery due to the thick media layer. Lesions have 
been described in aortic arch, descending aorta, pulmonary, coronary, renal artery, 
mesenteric arteries, and intracranial arteries.(Pober 2010)  Half of Williams-Beuren patients 
also suffer form hypertension, and cardiovascular disease is the most common cause of 
death in these patients.(Pober 2010; Pober and others 2008)  
4.5. Holt-Oram Syndrome 
Holt-Oram Syndrome (HOS) is also known as Heart-Hand Syndrome, and it manifests as 
congenital heart disease and upper limb dysplasia. The heart manifestations are mostly 
septal malformations and include secundum ASD, VSD, patent ductus arteriosus, and 
conduction system abnormalities. The upper limb malformations are widely variable but are 
typically bilateral and asymmetric in severity. They can range from a small abnormality 
such as a distally-placed thumb to phocomelia or hypoplasia of the shoulders and clavicles. 
Sometimes the upper limb dysplasia can go unnoticed and will be seen only after 
radiological imaging. Congenital heart malformations occur in 85% of HOS patients.(Basson 
and others 1994; Boehme and Shotar 1989)  
Genetically, HOS is an autosomal dominant disease caused by mutations in the TBX5 gene, 
a member of the T-box family of transcription factors. (Basson and others 1997; Li and others 
1997b) Haploinsufficiency of TBX5 was shown to be at the origin of the HOS. TBX5 interacts 
with other cardiac-specific transcription factors GATA4 and NKX2-5 to regulate the 
expression of downstream genes such as ID2, which are essential in septation of the cardiac 
chambers as well as development of the conduction system. The functional mechanisms 
through which the three transcription factors TBX5, GATA-4, and Nkx2-5 interact to mediate 
processes in heart development have been heavily studied, and there is a very complex 
network of interactions among these and other transcription factors and downstream genes 
that exists but that is still partially understood (Figure 1).  
Genotype-phenotype correlations were also performed in HOS, and it has been shown that 
TBX5 mutations that create null alleles result in more severe abnormalities in both upper 
limbs and the heart as compared to missense mutations.(Basson and others 1999) Some 
mutations caused very severe cardiac malformations but only subtle upper limb deformities.  
From a clinical perspective, it is important to look for subtle upper limb malformations in 
patients with septal deformities, because a diagnosis of HOS can increase the recurrence risk 
in a sibling from 3% to 50% given that this is an autosomal dominant disease. Clinical 
genetic testing for TBX5 has also become available in some laboratories across the world.  
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Figure 1. Complex Genetic Interactions of TBX5, GATA4, and Nkx2-5 (Network created using 
www.genemani.org ) 
4.6. Alagille Syndrome 
Alagille Syndrome is inherited in an autosomal dominant fashion and is defined in the 
presence of intrahepatic bile duct paucity that usually manifests as cholestasis, congenital 
heart disease, distinctive facies, skeletal, ocular, renal, and neurological abnormalities. 
(Kamath and others 2011; Li and others 1997a) CHD is found in more than 90% of patients 
with Alagille Syndrome and the most common lesion is Pulmonary Atery Stenosis (PAS) or 
hypoplasia. Other common lesions include TOF, pulmonary valve stenosis (PS), and 
ASD.(McElhinney and others 2002) The prevalence of the disease is estimated at around one 
in 700,000 neonates when presence of jaundice is used to ascertain cases (Danks and others 
1977), but in fact the disease has a tremendous variability in the phenotype and variable 
penetrance in families so that the actual prevalence is expected to be much higher.  
Alagille Syndrome is caused by mutations in the JAG1 gene.(Li and others 1997a; Oda and 
others 1997) The gene encodes a ligand to the Notch1 receptor. Jagged-Notch cell-cell 
interactions are crucial in determining cell fates during early developmental processes. The 
mutations spectrum of JAG1 in Alagille Syndrome encompasses frameshift mutations, 
nonsense mutations, splice site mutations, or deletion of the whole gene.(Yuan and others 
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1998) Mutations have also been identified in patients with a predominantly cardiac 
phenotype.(Li and others 1997a) Some families do have variable penetrance of the mutation 
as well as variant expressivity of the disease within the same family, such as facial 
dysmorphism only, or subtle liver disease only within members of the family carrying  
the same mutation.(El-Rassy and others 2008)  JAG-1 mutations are present in 94% of 
patients that are clinically diagnosed with Alagille Syndrome. A small number of cases are 
also explained by mutations in the Notch1 gene, the JAG-1 receptor.(McDaniell and others 
2006).  
Clinical testing for JAG-1 mutations is available. If patients are clinically diagnosed,  
a JAG-1 mutation could confirm the diagnosis, and indicate the need for multisystem 
assessment to look for other subclinical abnormalities and possibly prevent them. It would 
also allow for similar assessment of family members. Due to the high variability of the 
disease, patients with suspicious right-sided heart lesions such as PAS, TOF, and PS who  
do not necessarily fulfill the criteria for Alagille Syndrome could also be tested for JAG-1 
mutations. 
4.7. Noonan Syndrome 
Noonan Syndrome (NS) is a dysmorphic cardiofacial syndrome inherited mostly in an 
autosomal dominant fashion, with some cases occurring sporadically. Its incidence ranges 
between 1 in 1000 to 1 in 2500 live births.(Tartaglia and others 2010) The characteristic 
physical features are downward eyeslanting of the eyes, hypertelorism, low-set ears, short 
stature, short and webbed neck, and epicanthic folds.(Tartaglia and others 2010)  Congenital 
Heart Disease is found in 80 to 90% of patients with Noonan Syndrome and valvar 
pulmonary stenosis (PS) and Hypertrophic Cardiomyopathy (HCM) are the two most 
common cardiac manifestations. A large set of cardiac malformations can also occur 
including secundum ASD, AVSD, TOF, COA, VSD, PDA, and mitral valve disease.(Marino 
and others 1999; Noonan 1994)  Patients might also have deafness, cryptorchidism, motor 
delay, and bleeding diathesis.(Tartaglia and others 2010)  
NS is a genetically heterogeneous syndrome with at least 8 genes that have been associated 
with the disease so far: PTPN11, SOS1, RAF1, KRAS, BRAF, MEK1, MEK2, and 
HRAS.(Tidyman and Rauen 2009) Mutations in PTPN11 are most common and explain 50% 
of the Noonan Syndrome cases, the other 7 genes explain roughly 25% of the cases, and in 
about 25% of the cases no mutation is found.(Tartaglia and others 2010) All the genes 
implicated in NS encode proteins that are part of the Ras/Raf/MEK/ERK signaling pathway, 
an important regulator of cell proliferation, differentiation, and survival. PTPN11 encodes 
SHP-2, a protein tyrosine phosphatase that plays an important role in the signal 
transduction to medial the biological processes described above.  
Disease penetrance is almost complete with PTPN11 mutations, but there is a wide 
variability in the phenotype. Clinical testing for some of the genes involved in NS such as 
PTPN11, SOS1, and KRAS is available. Clinical diagnosis might be helpful might be helpful 
in borderline cases given the variability in the phenotype.  
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5. Nonsyndromic congenital heart disease 
Isolated congenital heart disease is the most prevalent form of CHD. Evidence for the 
genetic basis of isolated CHD comes from familial clustering of cases as well as higher 
recurrence rate of CHD.  Mutations in many genes have been associated with several CHD 
phenotypes, yet the evidence is variable for each gene. Gene mutations can best be classified 
as highly penetrant mutations in disease-causing genes, low-penetrance mutations in 
susceptibility genes, and common variants in CHD risk-genes. Transcription factor genes 
are the most common group of genes implicated in CHD. Other genes are part of signaling 
transduction pathways and structural components of the heart. Evidence for each gene 
comes from family studies and segregation analyses using direct sequencing. As mentioned 
earlier, one of the biggest challenges in the genetics of nonsyndromic CHD is that 
sequencing for all genes implicated in CHD explains the genetic cause of only a small 
percentage of patients. Most gene mutations have been described in one or few cases, while 
only a small number of genes have been duplicated in many cohorts and families.  
Table 3 lists all genes in which mutations have been found in different nonsyndromic CHD 
phenotypes. Most of these are based on only few cases and hence remain to be ascertained; 
however some have been duplicated in several families such as the phenotypes associated 
with NKX2-5 or GATA4 mutations. The table lists all the genes in which mutations have ever 
been described for each phenotype. The corresponding PubMed IDs are provided for the 
published studies where these gene mutations are reported so that readers can make their 
own assessment regarding the strength of the association.  
 
Phenotype Implicated Genes PubMed ID
Dextrocardia ACVR2B, NODAL, ZIC3 9916846, 19064609, 
14682828 
Tricuspid Atresia MYH6 15643620, 15389319 
Mitral Atresia FLNA 20730588 
Transposition of the Great 
Arteries (TGA) 
NODAL, FOXH1, CFC1, 
THRAP2, GDF1, ACVR2B, 
ZIC3, NKX2-5, MYH6 
9916847, 14638541, 
17924340, 11799476, 
18538293, 19553149, 
19933292, 19064609, 
17295247, 19933292, 
14681828, 18538293, 
1460745420656787 
Double Outlet Right Ventricle 
(DORV) 
NODAL, FOG2, GDF1, 
CFC1, ACVR2B, NKX2-5 
9916847, 17924340, 
11799476, 19553149, 
14681828, 20807224, 
14607454 
Common Arterial Trunk 
(CAT) 
GATA6, NKX2-5, Nkx2-6 19666519, 14607454, 
15649947 
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Tetralogy of Fallot (TOF) Nkx2-5, NODAL, CFC1, 
FOXH1, GATA4, FOG2, 
GDF1, HAND2, ALDH1A2, 
GATA6, TDGF1, JAG1 
20437614, 19886994, 
17924340, 16470721, 
18538293, 20581743, 
19553149, 18538293, 
18538293, 20819618, 
14517948, 14607454 
Total Anomalous Pulmonary 
Venous Connection (TAPVC) 
NODAL, PDGFRA, 
ANKRD1, ZIC3 
20071345, 18273862, 
19064609, 14681828 
Partial Anomalous Pulmonary 
Venous Connection (PAPVC) 
GATA4 18076106 
ASD NKX2-5, GATA4, GATA6, 
TBX20, CFC1, CITED2 
18159245, 1480002, 
15689439, 12845333, 
17072672, 19853937, 
19666519, 16287139, 
17668378, 9651244, 
15810002, 
15689439,14607454 
Ebstein ‘s Anomaly MYH7 21127202 
Atrioventricular Septal Defect 
(AVSD) 
NODAL, GATA4, ACVR1, 
CRELD1, CFC1, LEFTY2 
12845333, 20670841, 
19064609, 19506109, 
12632326, 15857420, 
18538293, 10053005 
Hypoplastic Left Heart 
Syndrome (HLH) 
NOTCH1, NKX2-5, GJA1, 
ZIC3 
18593716, 14607454, 
20456451, 11470490, 
14681828 
VSD NKX2-5, GATA4, CFC1, 
IRX4, ZIC3, TDGF1, 
CITED2, TBX20 
21544582, 12845333, 
17253934, 18055909, 
19853937, 14681828, 
19853938, 16287139, 
17668378, 12074273, 
9651244, 10587520 
Pulmonary Valve Stenosis 
(PS) 
ELN, GATA4, ACVR2B, 
ZIC3, GATA6 
21080980, 9916847, 
12845333, 19666519, 
14681828 
Pulmonary Artery Stenosis 
(PAS) 
ELN, JAG1 16944981, 11175284, 
10942104, 20437614 
Aortic Valve Stenosis (AS) NOTCH1, ELN, MYH6 21080980, 16025100, 
20656787 
Bicuspid Aortic Valve (BAV) NOTCH1 16729972, 160251100 
Supravalvar Aortic Stenosis 
(SVAS) 
ELN 9215670, 16944981, 
11175284 
Coarcation of the Aorta VEGF, NOTCH1, NKX2-5, 20420808, 10053005, 
 
Mutations in Human Genetic Disease 132 
(COA) LEFTY2 18593716, 14607454 
Interrupted Aortic Arch (IAA) CFC1, LEFTY2, NKX2-5 18538293, 10053005, 
14607454 
Patent Ductus Arteriosus 
(PDA) 
MYH11, TFAP2B 16444274, 17956658, 
18752453 
Table 3. Implicated Genes in Different Nonsyndromic CHD Phenotypes  
In the remaining part this section, the most common genes implicated in nonsyndromic 
CHD are discussed in details. For each gene, the mutational spectrum, function, associated 
CHD phenotypes, and mechanism of disease (if known) are provided. The three large 
groups of cardiac specific transcription factors, the GATA (GATA4, GATA5, and GATA6), 
Homebox (Nkx2-5 and Nkx2-6), and T-box (TBX1, TBX5, and TBX20) are first discussed in 
detail each in a separate subsection. These three categories of genes comprise the majority of 
the known genetic causes of CHD. Genes from all three categories interact to regulate 
downstream gene expression in the developing heart. Other transcription factor genes are 
discussed in a separate section. Different signaling pathway genes such as the NODAL 
signaling genes and the Notch signaling pathway are discussed separately. Contractile 
protein genes, in addition to their well-established role in cadiomyopathy, have been 
associated with CHD and are mentioned under one section. All remaining genes with 
minimal evidence for causing CHD comprise are clustered under the final subtitle of this 
section of the chapter.  
5.1. GATA transcription factors (GATA4, GATA5, GATA6) 
GATA-binding proteins are a family of transcription factors that regulate gene expression 
and are involved in cell differentiation, survival, and proliferation in many tissues. GATA 
proteins are evolutionary conserved proteins containing two zinc-finger motifs. They 
recognize and bind to a “GATA” consensus sequence, which is an important cis-element of 
the promoters of many genes. 
GATA4, GATA5, and GATA6 are involved in the developing heart, and knockout studies in 
mice have shown that all three are essential for normal cardiac development. Silencing of 
GATA genes can result in cardiac malformations ranging from valvoseptal defects to 
acardia. However, mutations in humans with CHD have been described only in GATA4 and 
GATA6 but not GATA5.  
GATA genes are also among the earliest transcription factors to be expressed in the 
developing heart.  They are expressed in different but overlapping time and tissue patterns 
in the embryonic heart and manifest complex combinatorial interactions. These 
characteristics seem to be essential for proper embryonic and postnatal cardiac 
development.  
GATA4 mutations are a well-established cause of CHD in humans. They are inherited in an 
autosomal dominant fashion in familial cases and are also seen in isolated cases. 
Haploinsufficiency of the GATA4 gene causes CHD, which is highly penetrant as observed 
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in familial studies. The most common phenotypes were causative GATA4 mutations are 
found are ASD, VSD, TOF, and AVSD.(Garg and others 2003; Nemer and others 2006) 
Findings of GATA4 mutations have been duplicated in many familial studies.(Chen and 
others 2010; Garg and others 2003) Multiple phenotypes are often seen within the same 
family segregating the same mutation. In isolated studies of CHD cohorts with phenotypes 
within the spectrum of phenotypes obtained from GATA4 knockout mice, the frequency of 
GATA4 mutations ranges between 0.8% and 3.7%.(Peng and others 2010; Rajagopal and 
others 2007; Tomita-Mitchell and others 2007; Zhang and others 2006)  The spectrum of 
mutations in GATA4 includes missense mutations as well as mutations that truncate the 
protein such as nonsense, frameshift, or splice site variants. Disease-causing missense 
mutations often disturb the cooperative binding of GATA4 to other transcription factors 
such as Nkx2-5 and TBX5 (Figure 1), a process which is essential for modulating 
downstream gene expression during cardiac development.  
Animal studies have shown that while Gata4+/- and Gata6+/- mice survive normally, 
compound heterozygous Gata4+/- Gata6+/- mice die at embryonic day 13.5 due to severe 
cardiac malformations.(Xin and others 2006) Also when both genes are knocked out 
completely, mice fail to develop any heart.(Zhao and others 2008) These studies have shown 
that both Gata4 and Gata6 are essential for cardiac development and that they interact to 
regulate downstream targets during heart development. Inactivating Gata6 in specific 
vascular cells using transgenic mice has also shown that Gata6 is involved in the migration 
of neural crest cells and differentiation of terminal smooth muscle cells, late processes in 
cardiac development.(Lepore and others 2006) Sequencing of patients with CHD 
corroborated animal findings by identifying heterozygous GATA6 mutations in outflow 
tract defects, mainly Common Arterial Trunk (CAT).(Kodo and others 2009) Subsequent 
studies showed that GATA6 mutations also cause ASD and TOF.(Lin and others 2010) Like 
for GATA4, the mutational spectrum of GATA6 includes missense as well as truncating 
variants, and genotype-phenotype correlations are not established as the same mutation can 
cause different phenotypes. In many laboratories around the world, clinical genetic testing is 
commonly available for GATA4, but not for GATA6.  
5.2. Homeobox transcription factors (NKX2-5, NKX2-6) 
Homeobox-containing genes are transcription factors that play crucial roles in cardiac 
development through regulating essential processes such as the spatio-temporal specificity 
of gene expression required for normal cardiac tissue differentiation. This transcription 
factor is evolutionary conserved and essential for cardiac development. The “Tinman” gene 
in drosophila is a homeobox-containing gene that is essential for development of the dorsal 
vessel, a structure analogous to the human heart. NKX2-5 is the “Tinman” homologue in 
mouse and is highly expressed in the mouse embryologic heart and essential for its 
development.(Reamon-Buettner and Borlak 2010) The NKX2-5 gene was cloned in 1996 
(Turbay and others 1996), and since then it was shown to be one of the most common 
known genetic causes of human CHD. 
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NKX2-5 plays critical roles in later stages of cardiac development, namely septation and 
development of the conduction system. It physically interacts with TBX5 to form a complex 
that cooperatively regulates downstream gene expression that is essential for proper 
septation and formation of the conduction system.(Habets and others 2002; Moskowitz and 
others 2007) Mutations in NKX2-5 gene cause congenital heart disease in an autosomal 
dominant fashion and with high penetrance.(Kasahara and others 2000) Many families have 
been described. The most common phenotype is ASD with Atrioventricular (AV) Block. 
However NKX2-5 mutations have also been associated with many other CHD phenotypes 
such as VSD, TOF, subvalvar AS, Ebstein’s Anomaly, cardiomyopathy, ventricular 
hypertrophy or non-compaction, and arrythmias other than the common AV 
block.(Reamon-Buettner and Borlak 2010) Also in families, different CHD phenotypes can 
be observed with the same NKX2-5 mutations making genotype-phenotype correlations 
difficult. In cohorts of isolated CHD, NKX2-5 mutations are found in around 2%.(Reamon-
Buettner and Borlak 2010)  The mutational spectrum is wide with missense and truncating 
mutations being heavily described. Sequencing for NKX2-5 is clinically available for genetic 
testing. Identifying family members through cascade screening might allow the diagnosis of 
fatal arrythmias or silent ASD’s that can otherwise lead to heart failure.  
NKX2-6 is another homeobox transcription factor that shares great homology with NKX2-6 
but whose downstream targets are unknown. Mouse in which NKX2-6 was knocked out did 
not have any cardiac phenotype, but one mutation has been associated with CAT in one 
family.(Heathcote and others 2005) More mutations in NKX2-6 remain to be detected in 
CHD patients with high throughput screening before its causality to CHD could be 
established.  
5.3. T-Box transcription factors (TBX1, TBX5, TBX20) 
The T-box family of binding proteins also consists of important transcription factors in 
cardiac development. T-box genes are evolutionary conserved and share a T-binding 
domain. All family members are involved in regulating developmental processes such as the 
initiation and potentiation of cardiac development.(Hariri and others 2011)  
The crucial role of TBX5 in heart development and its interactions with GATA4 and NKX2-5 
has been discussed earlier in this chapter. Apart from Holt-Oram Syndrome, TBX5 has not 
been implicated in nonsyndromic CHD, although some TBX5 mutations can cause a heart-
predominant phenotype with very subtle upper limbs disease. TBX1 was also discussed 
earlier as the cause of cardiac malformations in Di George Syndrome. A large deletion of 
57bp in the TBX1 gene was found in one non-syndromic patient with TOF.(Griffin and 
others 2010)  Apart from this single report, findings of TBX1 mutations have not been 
duplicated in non-syndromic CHD patients.  
Another member of the family that has been implicated in non-syndromic CHD is TBX20. 
Tbx20+/- mice have dilated cardiomyopathy and TBX20-/- mice die at midgestation due to 
grossly abnormal heart.(Stennard and others 2005) Mutations in TBX20 are found in less 
than 1% of patients with CHD phenotypes such as septal defects, left ventricular outflow 
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tract abnormalities, and HLH syndrome.(Kirk and others 2007; Posch and others 2010)  Both 
missense and nonsense heterozygous mutations are described. Functional studies suggest 
that both loss of function and gain of function mutations in the TBX20 gene can cause 
CHD.(Posch and others 2010)   
5.4. Other transcription factors (CITED2, ANKRD1, FOG2, ZIC3) 
The above three families of transcription factors are the most heavily studied in heart 
development, however a large set of other transcription factors have also been implicated in 
CHD, yet with lower degrees of evidence, or for some lower penetrance. This section will 
briefly discuss each of these transcription factors. 
CITED2 codes for CBP/p300-Interacting Transactivator with E/D-rich c-terminal Domain 
Type 2, a transcriptional co-activator several transcriptional responses such as TFAP2, the 
known cause of Char Syndrome. CITED2 null mouse embryos die embryologically and 
manifest septal, outflow tract, and aortic arch defects.(Bamforth and others 2004) CITED2 
mutations were detected in about 1% of sporadic cases of CHD. Phenotypes include ASD, 
VSD, and TAPVC.(Sperling and others 2005)  
Ankyrin Repeat Domain 1 (ANKRD1) is a transcription factor that interacts with cardiac 
sarcomere proteins. One balanced translocation and one missense mutation in ANKRD1 
gene were detected in two separate cases of TAPVC.(Cinquetti and others 2008)   
Friend of GATA 2 (FOG2) is, as its name implies, a cofactor of GATA4. FOG2 knockout mice 
have TOF-like phenotype,(Tevosian and others 2000) and FOG2 mutations have been 
described in TOF patients however with reduced penetrance.(Pizzuti and others 2003)  
ZIC3 encodes for a zinc finger transcription factor that is implicated in left-right axis 
development. It is a known gene in human situs abnormalities and is inherited in an X-
linked fashion. Mutations in ZIC3 have been identified in families and cohorts of 
heterotaxy.(Gebbia and others 1997) Additionally, there has been one reported family with 
TGA carrying a transversion in the ZIC3 gene, yet with incomplete penetrance.(Megarbane 
and others 2000)  
5.5. NODAL signaling genes (NODAL, GDF1, FOXH1, CFC1, ACVR2B,  
LEFTY2) 
The NODAL family of proteins is member of the TGF-beta superfamily of secreted signaling 
molecules. NODAL signaling is responsible for dorso-ventral patterning in vertebrate 
development as well as mesoderm and endoderm generation. Mutations in different genes 
in the NODAL signaling cascade are believed to occur and cumulatively decrease NODAL 
signaling leading to CHD phenotypes.(Roessler and others 2009) NODAL mutations have 
been reported in patients with heterotaxy, TGA, and conotruncal defects,(Gebbia and others 
1997; Mohapatra and others 2009) but as mentioned earlier simple heterozygosity is not 
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enough to cause the phenotype in the majority of cases. Mutations in other pathway genes 
such as GDF1, FOXH1, CFC1, and LEFTY2 are often necessary to cause disease.  
CFC1 (Cryptic) is a cofactor of NODAL signaling and its acts through activin receptors. 
CFC1 mutations have been initially reported in laterality defects.(Bamford and others 2000) 
However, outflow tract defects such as TGA and DORV have also been associated with 
CFC1 mutations.(Goldmuntz and others 2002) Similar associations with CHD phenotypes 
apart from situs abnormalities have been observed for GDF1, another member of the TGF-
beta superfamily involved in NODAL signaling.(Karkera and others 2007) FOXH1 
mutations have been associated with CHD however only within the context of reduced 
NODAL signaling due to mutations in more than one gene in the cascade.(Roessler and 
others 2008) Therefore, sequencing of all NODAL signaling genes together would give a 
better picture of the genetic cause of a particular CHD phenotype rather than identifying a 
variant in one of the genes.  
5.6. Notch signaling genes (NOTCH1, JAG1, NOTCH2) 
The Notch-Jagged signaling pathway is an important regulatory mechanism of cell 
differentiation processes during embryonic and adult life. In the heart, it is particularly 
important in cardiac valve development. JAG1 and NOTCH2 mutations are known causes of 
Alagille Syndrome. However mutations in both can cause non-syndromic CHD.(Bauer and 
others 2010; McDaniell and others 2006)  NOTCH1 has been also implicated in non-
syndromic CHD. Mutations can cause BAV, AS, COA, and HLH.(Garg and others 2005; 
McBride and others 2008; Mohamed and others 2006) 
5.7. Contractile protein genes (MYH6, MYH7, MYH11, MYBPC3, ACTC1) 
Mutations in contractile protein genes are common causes of Hypertrophic Cardiomyopathy 
(HCM) and other cardiomyopathies. However, some of these genes have also been 
implicated in a minority of CHD cases. One MYH6 (Alpha Myosin Heavy Chain) mutation 
has been described in a family with ASD. (Ching and others 2005) Mutations in MYH7  (Beta 
Myosin Heavy Chain) can cause Ebstein’s Anomaly and septal defects.(Budde and others 
2007) Heterozygous MYBPC3 mutations are a very frequent cause of HCM, however there 
have been reports of ASD and PDA in addition to severe HCM in patients with homozygous 
truncating mutations in the Myosin Binding Protein C gene MYBPC3.(Xin and others 2007; 
Zahka and others 2008) Similarly, mutations in Alpha-Cardiac Actin ACTC1, another 
sarcomere protein gene, cause ASD together with HCM.(Monserrat and others 2007) Finally, 
Myosin Heavy Chain 11 (MYH11) has a role in smooth muscles, and mutations in MYH11 
have been implicated in familial thoracic aortic aneurysm with PDA due to decreased 
elasticity of the aortic wall and the ductus arteriosus.(Zhu and others 2006)  
5.8. Miscellaneous genes (ELN, GJA1, FLNA, THRAP2) 
Elastin (ELN) deletion or mutations are implicated in Williams-Beuren syndrome, however 
have also been reported in many cases of isolated SVAS and PS. (Arrington and others 2006; 
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Metcalfe and others 2000) GJA1 encodes Connexin-43, a gap junction protein that maintains 
cell-cell adhesion and communication. Mutations in GJA1 were reported in a case of HLH 
and another report of heterotaxia patients. (Britz-Cunningham and others 1995; Dasgupta 
and others 2001) Filamin A (FLNA) cross-links actin filaments in the cytoplasm and anchors 
them to the rest of the cytoskeleton. FLNA is an X-linked gene in which mutations are 
associated with valvular dystrophy. (Kyndt and others 2007) Finally, mutations in the 
THRAP2 gene, which encodes a TRAP-complex protein, have been associated with TGA in 
one study.(Muncke and others 2003)   
6. Other genetic mechanisms of CHD 
Despite the large number of genes implicated in non-syndromic CHD, the genetic cause of 
the majority of isolated cases of CHD is still poorly understood. This has led researchers to 
investigate genetic mechanisms other than gene mutations that can contribute to inherited 
or isolated CHD. Copy Number Variations (CNVs), micro RNA (miRNA), somatic 
mutations, and epigenetics are all active areas of research into the genetics of CHD.  
6.1. Copy Number Variations 
Copy Number Variations (CNVs) are structural alterations to the genomic DNA that 
result in the cell having abnormal copies of large sections of its DNA. They can be 
inherited or occur de novo. Over the past decade, the role of CNVs in disease has been 
heavily studied, mostly in different types of cancers. In the heart, CNV analysis has 
explained an additional small fraction of the genetics of syndromic CHD (3.6%), but more 
of the non-syndromic CHD (19%).(Breckpot and others 2011) Submicroscopic deletions 
have been discovered using array-CGH in large CHD cohorts. CNVs occured in regions 
harboring known CHD candidate genes but were also capable of identifying new CHD 
loci in TOF, HLH, heterotaxy, and other CHD phenotypes.(Fakhro and others 2011; 
Greenway and others 2009; Payne and others 2012) One of the most commonly used 
strategies in CNV analysis is trio analysis, which allows the determination of de novo 
CNVs in CHD patients. Comparison with control groups is also helpful in assessing the 
likelihood of causality of CNVs using statistical methods. Despite several successful 
examples, the use of CNVs in understanding CHD remains challenging, particularly in 
proving the causality of the CNVs and assessing the magnitude that these CNVs have on 
the phenotype.  
6.2. Micro RNA 
Micro RNAs (miRNAs) are small (around 22 nucleotides long) single stranded noncoding 
RNAs and are encoded by miRNA genes. miRNAs serve as regulators of gene expression. 
Since cardiac development involves tremendous spatio-temportal specificity of gene 
expression, it is believed that miRNAs are involved in cardiac development and they can 
potentially cause CHD. miRNAs are important players in cellular proliferation, 
differentiation, and migration all of which are essential processes for proper cardiac 
 
Mutations in Human Genetic Disease 138 
development. In fact, cardiac specific miRNAs were discovered such as miR-133 and miR-1-
2, both of which when knocked out in mice cause cardiac defects, specifically VSD and 
dilated cardiomyopathy.(Ikeda and others 2007) miR-208a and miR-208b are also cardiac-
enriched, and they are encoded within the introns of MYH6 and MYH7.(Callis and others 
2009; van Rooij and others 2007) Current research focuses on sequencing miRNA to identify 
potential mutations that can cause CHD. Definite evidence in humans is still unavailable but 
might be underway.  
6.3. Somatic mutations 
Another direction of research to assess CHD is the study of somatic mutations using 
surgically discarded tissues from CHD patients who undergo surgical repair. Both DNA 
and RNA can be extracted and sequenced. Previous studies have focused on sequencing 
GATA4 and Nkx2-5 in somatic DNA of patients with septal defects, and yielded 
controversial findings as to whether somatic mutations contribute significantly to these 
genes.(Draus and others 2009; Esposito and others 2011; Reamon-Buettner and Borlak 2004) 
In the current era of high throughput DNA sequencing, and development of new analytical 
frameworks for RNA sequencing, the contribution of somatic mutations to CHD will 
become clearer soon, however no significant data in this field is published yet.   
6.4. Epigenetics 
The multifactorial causality of CHD has long been hypothesized to explain the complexity 
of the genetics of cardiac malformations. Epigenetics is one model where gene-environment 
interaction can affect gene expression and disturb developmental processes in the 
embryonic heart. Histone modifications and chromatin remodeling both play important 
roles in cardiac development and physiology(Han and others 2011; Lange and others 2008; 
Ohtani and Dimmeler 2011), and recent studies shoed that they can directly interact with 
some classes of transcription factors like the T-box family.(Miller and Weinmann 2009) It is 
possible that epigenetic mechanisms contribute to the etiology of CHD, however more 
evidence remains to be established.  
7. Current tools for the genetic evaluation of CHD 
Different techniques are currently available to interrogate the genetic causes of CHD. 
Karyotyping and Fluorescent In-Situ Hybridization (FISH) analysis remain the best tools to 
assess chromosomal deletions or rearrangements. They are often the starting point for the 
genetic assessment of a CHD patient.  Whenever candidate genes are suspected, for 
instance in the setting of a clinically diagnosed syndrome, Sanger sequencing is performed 
on the candidate gene to look for disease-causing mutations. For many years, together with 
positional mapping through linkage analysis, these were the only tools that drove genetic 
discovery in CHD in humans. Current technology makes use of array-comparative 
genomic hybridization (array-CGH) for linkage analysis, Genome Wide Association 
Studies (GWAS), CNV analysis, homozygosity mapping, and transcriptome analysis. More 
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importantly was the introduction of next-generation sequencing in 2005 and the 
tremendous decrease in the cost of sequencing over the past several years, which is 
allowing the massive sequencing of the exome and even genome of huge numbers of 
patients. Next-generation RNA sequencing is also beginning to be used to sequence cardiac 
transcripts from CHD patients who have underwent surgery. The rapid pooling of high 
throughput data is expected to massively increase our understanding of CHD within the 
coming two years. To deal with these large amounts of data, bioinformatics and modeling 
of genetic variants determine function is becoming the standard and many molecular 
biology labs are forced to become genetics and bioinformatics labs to make use of current 
technology. A systems biology approach is needed nowadays to integrate high throughput 
data from the many possible sources.  
8. From the bench to the bedside 
With the advances in sequencing and bioinformatics, gene discovery in CHD is escalating. 
This advance in research is directly translated to clinical testing to provide genetic 
counseling for adult patients with CHD who plan to have children. From a technical aspect, 
our capability to identify genetic variants in CHD genes has magnified. Nonetheless, 
making functional significance and even clinical sense of the large number of gene 
mutations remains a big challenge. Given the complexity of CHD, definite gene mutations 
remain uncommon. At this time when the genetic inflow of information is very fast, 
physician-scientists must be very careful in communicating genetic information that is not 
validated to patients, in order to avoid psychological and emotional harm. On a different 
angle, with sequencing of the exome or genome, the chances of detecting incidental findings 
that indicate disease risk or prognosis becomes very high. All such unintentionally detected 
serious genetic findings are termed the incidentalome.(Kohane and others 2006) Since CHD 
is mostly surgically treated and people who undergo genetic testing are often already cured, 
caregivers need to be cautious before rushing next-generation sequencing into the CHD 
clinic.  
9. Future prospects 
Current trends in CHD genetics research are making use of the rapidly developing 
technology, particularly high throughput sequencing. This trend will continue over the 
coming few years. The challenge is in integrating the increasing amounts of data to answer 
the questions that need to be answered. Systems biology and innovative bioinformatics tools 
are crucial to integrate data from different sources and build a pipeline that can unravel the 
mysteries that molecular biologists have been trying to answer for many years.  
Eventually, more validated genetic information will be available in the clinic to allow 
accurate genetic counseling and prenatal screening. Understanding heart development will 
also allow for possible therapeutic applications given the many-shared molecular pathways 
between embryologic heart development and adult heart disease, particularly tissue death 
and regeneration in the setting of ischemic heart disease.  
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